Uso de ácido acetil salicílico (ASA) 150mg hasta semana 36 como reducción del riesgo de preeclampsia de inicio temprano y tardío
| dc.contributor.author | Rizo Obregón, Karen Lorena | |
| dc.date.accessioned | 2020-01-14T21:24:10Z | |
| dc.date.available | 2020-01-14T21:24:10Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | La preeclampsia es una de las patologías las cuales generan una alta tasa de mortalidad tanto materna como fetal a través del tiempos se ha logrado establecer la importancia del ácido acetil salicílico (ASA) como reductor de riesgo de esta patología en el cual por medio de este trabajo se demuestran los beneficios para la reducción de riesgo de preeclampsia y pronostico fetal. | spa |
| dc.description.abstract | Preeclampsia is one of the pathologies which generate a high maternal and fetal mortality rate over time, it has been possible to establish the importance of acetylsalicylic acid (ASA) as a risk reducer of this pathology in which through this scientific article we will demonstrate the benefits for the reduction of risk of preeclampsia and fetal prognosis | eng |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/4511 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Preeclampsia | spa |
| dc.subject | Ácido acetil salicílico | spa |
| dc.subject | Preeclampsia temprana | spa |
| dc.subject | Restricción de crecimiento fetal | spa |
| dc.subject | Acetylsalicylic acid early | eng |
| dc.subject | Fetal growth restriction | eng |
| dc.title | Uso de ácido acetil salicílico (ASA) 150mg hasta semana 36 como reducción del riesgo de preeclampsia de inicio temprano y tardío | spa |
| dc.title.alternative | Use of acetylsalicylic acid (ASA) 150 mg untilweek 36 as a reduction in the risk of early and late onset preeclampsia | eng |
| dc.type | Other | spa |
| dcterms.references | Centro latinoamericano de Perinatología Salud reproductiva y de la Mujer OMS edición Mayo 2019 pagina 60-65 | spa |
| dcterms.references | Low Douse Of Aspirin And Pregnancy K. navaraham Z. Revic British Journal Of Obstetrics And Gynecology Edition Mayo 2019 pagina 1481-1490 | eng |
| dcterms.references | Trastornos hipertensivos asociados a embarazo K. Nicolaides A. ambrosi American Collage Of Obstetrics And Gynecology June 2019 Paginas 85-95 | eng |
| dcterms.references | Apirin for prevention of preterm and term preclampsia : systematic review and metaanalysis K. nicolaides E. Bujold S. Roberge American Journal Of Obstetrics And Gynecology junio 2017 paginas 287-291 | eng |
| dcterms.references | Aprin for prevention of preeclampsia A. Atalllah E. Lecarpentier F. Goffinet V Tsatsaris American Journal Obstetrics And Gynecology Marzo 2018 | eng |
| dcterms.references | Aspirina Vs Placebo en embarazos con alto riesgo de preeclampisa temprana ASPRE New England Journal Of Medicine K. Nicolaides P. Matallana S. Cicero Agosto 2017 pagina 23-30 | spa |
| dcterms.references | Manejo expentante de preeclampisa severa de inicio temprano estudio MEXPRE P. vigil A. Villar J. Lmir American Journal Obstetrics And Gynecology 2015 paginas 34 - 38 | spa |
| dcterms.references | Apirine: idications et utilisation durant la grossesse N. Belhomme C. Doundnikoff E. Polard Ultrasound Journal Mayo 2019 pagina 10-25 | eng |
| dcterms.references | The practica use of acetylsalicylic acid in the era of the ASPRE trial P. Kosinki U. Sarzynka-Nowacka M. Fiolna Fetal Medicine Foundation Abril 2019 paginas 24- 34 | eng |
| dcterms.references | Riesgo de preeclampsia y evento perinatal adverso en pacientes Clinicas de Norteamerica 2019 | spa |
| dcterms.references | Pritchard JA, Weissman R, Ratnoff OD, et al. Intravascular hemolysis,trombocitopenia, and other hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med.1954; 250: 89-98 | eng |
| dcterms.references | World Health Organization (WHO), recommendations for Prevention and treatment of preeclampsia and eclampsia, 2011. | eng |
| dcterms.references | Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy. Aust N Z J Obstet Gynaecol. 2015. | eng |
| dcterms.references | Pennington KA, Schlitt JM, Jackson DL, Schulz LC, Schust DJ. Preeclampsia: múltiple approaches for a multifactorial disease. Dis Model Mech. 2012; 5:9-18 | eng |
| dcterms.references | Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S. Management of hypertensive disorders during pregnancy: summar y of NICE guidance. 2010. | eng |
| dcterms.references | Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007. | eng |
| dcterms.references | Valdés E, Sepúlveda-Martínez Á, Tong A, Castro M, Castro D. Assessment of Protein: Creatinine Ratio versus 24-Hour Urine Protein in the Diagnosis of Preeclampsia. Gynecol Obstet Invest. 2016; 81:78-83. | eng |
| dcterms.references | Demirci O, Kumru P, Arınkan A, Ardıç C, Arısoy R, Tozkır . Spot protein/creatinine ratio in preeclampsia as an alternative for 24-hour urine protein. Balk Med J. 2015. | eng |
| dcterms.references | Cade TJ, Gilbert SA, Polyakov A, Hotchin A. The accuracy of spot urinary protein-to-creatinine ratio in confirming proteinuria in pre-eclampsia. Aust N Z J Obstet Gynaecol. 2012 | eng |
| dcterms.references | Restrepo M, Arango V, Gil-Pabón C, Campo-Campo M, Echavarría-Restrepo L. Evaluación de las características operativas de la relación proteína / creatinina en orina ocasional para la detección de proteinuria significativa en gestantes con sospecha de preeclampsia. Revista Colombiana de Obstetricia y Ginecología. 2016 | spa |
| dcterms.references | Shimajuko R, Rodríguez H, Uriol R, Lázaro H, Vera M. Relación proteina creatinina en orina para el diagnóstico de preeclampsia. 2013 | spa |
| dcterms.references | Ginsberg, J.M.; Chang, B.S.; Matarase, R.A.; Garella, S.: Use of single voided urine | eng |
| sb.programa | Especialización en Ginecología y Obstetricia | spa |
| sb.sede | Sede Barranquilla | spa |
Archivos
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 2.93 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: